David M. Kakiashvili

David M. Kakiashvili

Date of Birth:  June 16, 1969

Place of Birth:  Tbilisi, Georgia

Date of Immigration to Israel:  1994

Citizenship:  Israeli

Military Service:

Lieutenant of Israeli Defense

Army, Senior Medical Officer

Current Address:

Department of Urology, RAMBAM

Health Care Campus,

Haifa 31096, Israel.

Personal Information:  Single

Languages:  English, Hebrew, Russian, Georgian

 

CURRENT POSITION:

Director of Urologic Oncology

Director of Robotic Surgery

Rambam Health Care Campus

 

MEDICAL EDUCATION

 

Academic Degrees, Diplomas, Licensure and Certifications

1988-94                                                               M.D., Tbilisi State MedicalUniversity

Tbilisi, Georgia

Subject: Doctor of Medicine

1996                                                                       M.D., Israeli Ministry of Health

Jerusalem, Israel

Subject: Doctor of Medicine

1996-1997                                                              RAMBAM Medical Center

The Technion School of Medicine

Haifa, Israel

Subject: Rotation Internship

 

SPECIALITY TRAINING:

1998-2006                                                              RAMBAM Medical Center

The Technion School of Medicine

Department of Urology

Haifa, Israel

Supervisor: Dr. S. Meretyk

Subject: Postgraduate Trainee,

2004                                                                      Advance Trauma Life Support (ATLS)

(Certificate)

2005-2006 Baylor College of Medicine

Scott Department of Urology

Houston, Texas, USA

Subject: Basic Research (Certificate)

* Topic: “BLADDER AUGMENTATION USING A BIOLOGICAL ACELLULAR MATRIX IN SMALL AND LARGE ANIMAL MODELS” (Approved by Israeli Scientific Council)

April, 2006                                                       Baylor College of Medicine

Scott Department of Urology

Houston, Texas, USA

Subject: American Urologic Association

Guided Course in Advance Laparoscopy

June, 2006                                                       Israeli Board Recognized Urologic Surgeon

Subject: License, Medical Council &

Ministry of Health, Israel

 

FELLOWSHIP(s):

2005-2006                                                        Baylor College of Medicine

Scott Department of Urology

Houston, Texas, USA

Supervisor(s): Dr. Seth P. Lerner and

Dr. Gilad E. Amiel

Subject: Research Fellowship in Tissue

Engineering and Urinary Bladder

(Certificate)

2006-2008                                                        University of Toronto

Toronto, Ontario, Canada

Supervisor(s): Dr. Laurence Klotz &

Dr. Neil E. Fleshner

Subject: Society of Urologic Oncology

(SUO) Guided Fellowship in Urologic

Oncology (Research & Clinical)

(American SUO Certificate)

2008-2009                                                        University of Toronto

Toronto, Ontario, Canada

Supervisor(s): Dr. Neil E. Fleshner

Subject: Clinical Fellowship in daVinci

Robotic Urologic Surgery

(Certificate)

September, 2008                                               The Global Robotic Institute

Orlando, Fl. USA

Supervisor(s): Dr. Vipul Patel

Subject: DaVinci Console Trained Surgeon

(Certificate)

September 1, 2009                                            RAMBAM Medical Center

The Technion School of Medicine

Department of Urology

Haifa, Israel

Subject: Active Staff

January 1, 2009                                                 Director of Uro-Oncology

Department of Urology

Rambam Health Care Campus,

P.O.B 9602; Haifa, 31096, Israel

 

CURRENT POSITION

January 1, 2010                                                 Director of Robotic Surgery

Director of Uro-Oncology,

Rambam Health Care Campus,

P.O.B 9602; Haifa, 31096, Israel

 

PUBLICATIONS

  1. van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, Zlotta AR. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. Eur Urol. 2011 Oct 25. [Epub ahead of print]
  2. Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumeguere T, Shariat SF, Rorive S, Zlotta AR. Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. Urol Ann. 2011 Sep;3(3):119-26.
  3. Kakiashvili DM1,Van Rhijn BWG1,2, Jewett MAS1, Fleshner NE1, Azuero J1, Bangma CH2, Alkhateeb S1, Kostynsky A,1 Van Der Kwast TH3,4 , Zlotta AR1. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment; BJU Int. 2011 Feb;107(4):540-6. doi: 10.1111/j.1464-410X.2010.09572.x. Epub 2010 Sep 7.
  4. J.F.G. Sturgeon, M.J. Moore, D. Kakiashvili, I. Duran, L. Anson-Cartwright, D. R. Berthold, P. R. Warde, M. Gospodarowicz, R.E. Alison, J. Liu, C. Ma, G. R. Pond, & M.A.S. Jewett*. Non-Risk Adapted Surveillance in Clinical Stage I Non-Seminomatous Germ Cell Tumors (NSGCT): The Princess Margaret Hospital’s Experience; Eur Urol. 2010 Dec 22. [Epub ahead of print]
  5. van Rhijn BW, van der Kwast TH, Kakiashvili DM, Fleshner NE, van der Aa MN,  Alkhateeb S, Bangma CH, Jewett MA, Zlotta AR. Pathological stage review is indicated in primary pT1 bladder cancer.BJU Int. . [Epub ahead of print]
  6. Zuniga A, Kakiashvili D, Jewett MAS. Surveillance in stage I nonseminomatous germ cell tumors. BJU Int. 2009 Nov; 104(9 Pt B):1351-6.
  7. Kakiashvili DM, Zuniga A, Jewett MAS. High Risk NSGCT: case for surveillance. World Journal of Urology; 2009 Aug; 27(4):441-7. Epub 2009 Jul 16.
  8. Golijanin DJ*, Kakiashvili D*, Madeb RR, Messing EM, Lerner SP. Chemoprevention of Bladder Cancer. World Journal of Urology; 2006 Nov; 24(5):445-72. Review. * Equal contribution.
  9. Halachmi S, Kakiashvili D, Meretyk S. A Review of Hematuria in Children. Scientific World Journal; 2006 Mar 8; 6:311-7. Review
  10. Halachmi S, Kakiashvili D, Meretyk S. Hematuria in Children. Harefuah; 2006 Jan; 145(1):52-6, 76.Review.

 

SUBMITTED

  1. Peter J. Bostrom, David M. Kakiashvili, Malcom J. Moore, Jeremy F. Sturgeon, Padraig R. Warde, Mary K Gospodarowicz, Peter Chung, Lynn C. Anson-Cartwright, Martin O’Malley, Joan Sweet, Ruth E. Alison, Michael A.S. Jewett*. Treatment of Stage II-III Nonseminatous Germ Cell Tumors after Chemotherapy with Risk-Adapted Approach: Long Term Experience from The Princess Margaret Hospital. Ann. Oncology

 

PAPERS IN PROGRESS 

  1. Kakiashvili DM, Moore MJ, FG Sturgeon JFG, Anson-Cartwright L, Warde PR, Zuniga A, Chung P, Liu J, Ma C, Jewett MAS. Primary Retroperitoneal Lymph Node Dissection for Low Stage Non-Seminomatous Germ Cell Testicular Tumors (NSGCT), Including as Salvage for Surveillance Progression. Journal of Clinical Oncology (JCO).
  2. Kakiashvili DM, Anson-Cartwright L, Moore MJ, FG Sturgeon JFG, Warde PR, Zuniga A, Chung P, Liu J, Ma C, Jewett MAS. Patterns and Detection of Relapse in Clinical Stage I nonseminomatous Germ Cell Testis Tumors on Surveillance: recommendation for Follow-up. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
  3. Kakiashvili DM, Anson-Cartwright L, Moore MJ, FG Sturgeon JFG, Warde PR, Zuniga A, Chung P, Liu J, Ma C, Jewett MAS. Prognostic Risk Factors for Progression in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors Managed by Active Surveillance. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
  4. Amiel GE, Shu T, Ramsey D, Jian W, Jin W, Bellows C, Kakiashvili DM, Lerner SP. OUTCOME OF BLADDER AUGMENTATION WITH NOVEL BIODEGRADABLE MATRIX IN A PORCINE MODEL. The Scott Department of Urology, Baylor College of Medicine, Houston, TX

 

OTHER PUBLICATIONS/PRESENTATIONS

 

Presentations in National Meetings & International Conferences 

  1. Kakiashvili D, Anson-Cartwright L, Sturgeon JFG, Warde PR, Chung P, Moore M, Wang L, Azuero J, Jewett MAS, Toronto, ON, Canada. NON RISK- ADAPTED SURVEILLANCE MANAGEMENT FOR CLINICAL STAGE I NONSEMINOMATOUS TESTIS TUMORS. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital,University Health Network, University of Toronto, Toronto, Ontario, Canada (AUA, 2007; CUA, 2007; ASCO, 2007; EUA, 2008)
  2. Kakiashvili D, Anson-Cartwright L, Sturgeon JFG, Warde PR, Chung P, Moore M, Wang L, Azuero J, Jewett MAS, Toronto, ON, Canada. PATTERNS AND DETECTION OF RELAPSE IN CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TESTIS TUMORS ON SURVEILLANCE: RECOMMENDATIONS FOR FOLLOW-UP. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (AUA, 2007; CUA, 2007)
  3. Kakiashvili D, Anson-Cartwright L, Sturgeon JFG, Warde PR, Chung P, Moore M, Wang L, Azuero J, Jewett MAS, Toronto, ON, Canada. PROGNOSTIC RISK FACTORS FOR PROGRESSION IN CLINICAL STAGE I NONSEMINOMATOUS TESTICULAR GERM CELL TUMORS MANAGED BY SURVEILLANCE. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (CUA, 2007)
  4. Kakiashvili D, Anson-Cartwright L, Moore M ,Sturgeon JFG, Warde PR, Chung P, Wang L, Azuero J, Jewett MAS, Toronto, ON, Canada. PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION FOR CLINICAL LOW STAGE NONSEMINOMATOUS GERM CELL TESTICULAR TUMORS. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. * BEST PAPER: American Urology Association (AUA), 2008; CUA, 2008
  5. Kakiashvili D, Anson-Cartwright L, Moore M ,Sturgeon JFG, Zuniga A, Warde PR, Chung P, Liu J, Jewett MAS, Toronto, ON, Canada. POST-CHEMOTHERAPHY RETROPERITONEAL LYMPH NODE DISSECTION OF RESIDUAL RETROPERITONEAL MASS FOR TESTICULAR GERM CELL TUMORS: IS BILATERAL TEMPLATE NECESSARY? Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. * BEST PAPER: Canadian Urology Association (CUA) 2008, 5-star distinction
  6. Kakiashvili D, Azuero J, Fleshner NE, Jewett MAS,  Kostynskyy A, Finelli A, Jarvi K, Van Der Kwast T, Zlotta AR, Toronto, ON, Canada. LONG TERM RESULTS OF BCG IN THE TREATMENT OF T1G3 BLADDER CANCER. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada (CUA, 2008)
  7. Kakiashvili D, Anson-Cartwright L, Moore M ,Sturgeon JFG, Zuniga A, Warde PR, Chung P, Liu J, Jewett MAS, Toronto, ON, Canada. POST-CHEMOTHERAPHY RETROPERITONEAL LYMPH NODE DISSECTION OF RESIDUAL RETROPERITONEAL MASS FOR TESTICULAR GERM CELL TUMORS: IS SURGERY INDICATED IN ALL AND IS BILATERAL TEMPLATE NECESSARY? Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. * BEST PAPER: (European Urology Association (EUA) 2009*; AUA, 2009)
  8. Kakiashvili D1,Van Rhijn BWG1,2, Jewett MAS1, Fleshner NE1, Azuero J1, Kostynsky A,1 Bangma CH2, Van Der Kwast TH3,4 , Zlotta AR1, Toronto, ON, Canada.  LONG-TERM FOLLOW-UP FOR PRIMARY T1 HIGH-GRADE BLADDER CANCER. DOES BCG REALLY PREVENT PROGRESSION? Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada1, Department of Urology, Erasmus MC, Rotterdam, The Netherlands2, Department of Surgical Pathology, University Health Network, Toronto, Ontario, Canada3, Department of Pathology, Erasmus MC, Rotterdam, The Netherlands4 (EUA, 2009)
  9. Amiel GE, Shu T, Ramsey D, Jian W, Jin W, Bellows C, Kakiashvili D, Lerner SP. ONE-YEAR OUTCOME OF BLADDER AUGMENTATION WITH NOVEL BIODEGRADABLE MATRIX IN A PORCINE MODEL. The Scott Department of Urology, Baylor College of Medicine, Houston, TX (AUA, 2008)
  10. Van der Kwast TH 1, Van der Aa M2, Kakiashvili D3, M Jewett MAS 3, Zlotta AR3 and Van Rhijn BW 3, Toronto, ON, Canada. IMPACT OF PATHOLOGY REVIEW AND SUBSTAGE ON THE CLINICAL OUTCOME OF pT1 BLADDER CANCER. Pathology, University Health Network, Toronto, Ontario, Canada1, Pathology, Erasmus MC, Rotterdam, Netherlands2 and   Urology, University Health Network, Toronto, Ontario, Canada3. (EUA, 2009)
  11. Alkhateeb S1, Neill M1, Bar-Moshe S2,Van Rhijn B1, Kakiashvili D1, Fleshner N1, Jewett MAS1, Petein M2, Schulman C2, Roumeguere T2, Rorive S2 and Zlotta AR.1 WHAT IS THE LONG TERM PROGNOSTIC VALUE OF PRO-APOPTOTIC, ANTI-APOPTOTIC, PROLIFERATION AND INVASIVENESS MOLECULAR MARKERS IN PATIENTS TREATED WITH BCG WITH HIGH RISK NON-INVASIVE BLADDER CANCER? 1 Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada . 2 Department of Urology, Erasme Hospital, University Clinics of Brussels, Brussels, Belgium. (EUA, 2009; AUA, 2009)
  12. Mir C+, Shariat S^, Van der Kwast TH$, Ashfaq R@, Lotan Y@, Skeldon S*, Hanna S*, Alkhateeb S*, Kakiashvili D*, Morote J+,Van Rhijn B*, Fleshner N*, Jewett M*, Zlotta AR*. ANDROGEN RECEPTOR (AR) AND BLADDER CANCER:A LARGE BI-INSTITUTIONAL STUDY ON 473 PATIENTS.*Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital,  University Health Network, University of Toronto, Toronto, Canada, $ Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, Canada,@ Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas,+ Departments of Urology, Vall d’Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain.^Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York. (EUA 2009)
  13. Bas WG van Rhijn*, Theo H van der Kwast, David Kakiashvili, Neil E Fleshner, Madelon NM van der Aa, Rati Vajpeyi, Sultan Alkhateeb, Chris H Bangma, Michael AS Jewett, Alexandre R Zlotta. Dep. of Urology & Pathology, UHN & Mount Sinai Hospital, Univ. of Toronto, Canada and Dep. Of Urology, Erasmus MC, Rotterdam, NL. IMPACT OF SUB-STAGE ON THE CLINICAL OUTCOME OF pT1 BLADDER CANCER: COMPARISON OF TWO SUB-STAGING SYSTEMS. Departments of Surgical Oncology (Division of Urology) , Princess Margaret Hospital, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada1, Department of Urology, Erasmus MC, Rotterdam, The Netherlands2, Department of Surgical Pathology, University Health Network, Toronto, Ontario, Canada3, Department of Pathology, Erasmus MC, Rotterdam, The Netherlands4

 

OTHER LECTURES OR PAPERS GIVEN

  1. Invited speaker at the Department of Urology, McGill University School of Medicine, Montreal, Quebec, September, 2009. Post- Chemotherapy Retroperitoneal Lymph Node Dissection for Low Stage Non-Seminomatous Germ Cell Testicular Tumors: Is surgery indicated in all and is bilateral template necessary?
  2. Annual Charles Robson Lecture Series in Urology, University of Toronto,Toronto,Ontario,Canada,April,2007. Non-Risk Adapted Surveillance in Clinical Stage I Non-Seminomatous Germ Cell Tumors (NSGCT)
  3. Annual Charles Robson Lecture Series in Urology, University of Toronto,Toronto,Ontario,Canada,May,2008. Primary Retroperitoneal Lymph Node Dissection Low Stage Non-Seminomatous Germ Cell Testicular Tumors
  4. “Leaving With Prostatic Cancer Foundation”,Rambam Health Care Campus,Haifa,Israel,May,2011; daVinci Robotic Surgery: Surgical Precision Beyond the Limits of the Human Hand
  5. Annual Meeting for Israeli Comunity Urologists,Kfar Bloom,Israel, June,2011; “Urothelial TCC: the 2011 Guidlines”
  6. Invited Speaker at The First International Polish Robotic Surgical Society Meeting,Wroclaw,Poland, March 2012

 

SPECIAL EVENTS

Performing live surgery (robot assisted radical prostatectomy) at The First International Polish Robotic Surgical Society Meeting,Wroclaw,Poland, March 2012

 

SCIENTIFIC MEETINGS ATTENDED

 

2000     Annual Meeting of the Israel Urologic Association, Jerusalem

2001     Annual Meeting of the Israel Urologic Association, Eilat

2002     Annual Meeting of the Israel Urologic Association, Eilat

2002     European Urology Association School (Balkan meeting), Belgrade

2003     Annual Meeting of the Israel Urologic Association, Eilat

2004     AUA (American Urologic Association) annual meeting, San Francisco,California

2005     AUA, San-Antonio,Texas

2006     SUO ( Society of Urologic Oncology) annual meeting,Bethesda,MD

2006     AUA, Atlanta, Georgia

2007     SUO  annual meeting,Bethesda,MD

2007     AUA, Anaheim, California

2007     CUA, Quebec City, Quebec

2008     SUO  annual meeting,Bethesda,MD

2008     AUA, Orlando, Florida

2008     CUA, Edmonton, Alberta

2009     EUA (European Urologic Association) annual meeting, Stockholm, Sweden

2009     AUA annual meeting, Chicago, Illinois

2010     IRUS Robotic Surgery Conference, Las Vegas, Nevada

2010     AUA annual meeting, San Francisco, California

2011     AUA annual meeting, Washington DC, CD

 

HONOURS, GRANTS AND AWARDS RECEIVED

  1. “Excellent Young Lector” Award, Faculty of Medicine, The Technion School of Medicine, Israel Institute of Technology, Haifa, Israel. 2001
  2. Best paper, AUA (American Urologic Association) annual meeting, Orlando, Florida.  2008
  3. Best paper, CUA (Canadian Urologic Association), Edmonton.  2008
  4. Best paper, EUA (European Urologic Association), Stockholm, Sweden.  2009
  5. Israel Cancer Association Annual Research Grant for Basic Research in the field of Cancer. 2005
  6. APF (American Physician Fellowship for Israel) Annual Grant in the field of basic research. 2005
  7. Israeli Medical Association annual Research Grant. 2005

 

MEDICAL JOURNAL REVIEWER

European Journal of Urology 2007- Present

 

ONGOING REASERCH  PROJECTS

 

BASIC REASERCH 

Analysis of peptides presented on MHC-Class I molecules isolated from tumor cells. PI (Principal Investigator)

-Validation of anti-cancer therapy targets presented in kidney, prostate and bladder tumors.

-Determination of T cell receptor like (TCRL) antibodies (affinity and specificity), which were engineered by AIT against selected targets.

 

CLINICAL REASERCH

daVinci Robotic Surgery

–  “TREEFECTA “– assessment of 3 most important outcome variables after radical prostatectomy: Cancer control, continence and potency rates: Comparison between robotic and open radical prostatectomy.

–  Positive surgical margins: Comparison analysis between robotic and open radical prostatectomy

– Immediate vs long-term patients’ satisfaction: Comparison analysis between robotic and open radical prostatectomy

 

* SURGICAL INTEREST

  1. daVinci ROBOT-ASSISTED LAPAROSCOPIC NERVE-SPARING ONCOLOGIC SURGERY (RADICAL PROSTATECTOMY, RADICAL CYSTECTOMY), NEPHRECTOMY, PARTIAL NEPHRECTOMY,ADRENALECTOMY
  2. NERVE-SPARING PRIMARY AND POST-CHEMOTHERAPY RETROPERITONEAL LYMPH NODE DISSECTION FOR TESTICULAR CANCER
  3. NERVE-SPARING RADICAL CYSTECTOMY WITH CONTINENT ORTHOTOPIC DIVERSIONS (NEOBLADDER)
  4. RETROPERITONEAL AND PELVIC TOMOURS